Erythromycin can suppress the transcriptional activity of NF-κB, the activator protein-1 (AP-1), and its downstream targets, IL-6 and cyclooxygenase-2 (COX-2), in human CRC cells [81]. This evidence concerns the gene PTGS2 and colorectal carcinoma.